# Expedited Programs for Regenerative Medicine Therapies for Serious Conditions:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/expedited-programs-for-regenerative-medicine-therapies-for-serious-conditions-guidance-for-industry/8797d365-c489-4514-ab4e-b382ecf2661c

> FDA guidance document: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions:  Guidance for Industry. Issue date: February 15, 2019. Get complete insights and analysis.

---

## Details

- Title: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Biologics Evaluation and Research
- Office URL: /offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d
- Issue Date: 2019-02-15
- Comment Close Date: 2018-02-15
- Last Changed: 2019-05-16
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-6159">FDA-2017-D-6159</a>

## Related Documents

- [Considerations for the Development of Dried Plasma Products Intended for Transfusion:   Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/considerations-for-the-development-of-dried-plasma-products-intended-for-transfusion-guidance-for-industry/c0c693ab-7392-4bad-b4c9-de122a24ced4)
- [Recommendations for Microbial Vectors Used for Gene Therapy:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/recommendations-for-microbial-vectors-used-for-gene-therapy-guidance-for-industry/bdeabfdf-bbbe-4b57-a5be-ef92ff0cf1bd)
- [Human Gene Therapy for Hemophilia:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/human-gene-therapy-for-hemophilia-guidance-for-industry/bceafce9-c9f0-4137-9ca5-071464212a06)